NCT02565719View on ClinicalTrials.gov

REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Chronic Hepatitis B
Interventions
DRUG

REP 2139-Mg

REP 2139-Mg = magnesium chelate complex of REP 2139

DRUG

Pegasys

immunotherapy

DRUG

Viread

HBV RT polymerase inhibitor

DRUG

REP 2165-Mg

REP 2165-Mg = magnesium chelate complex of REP 2165

Trial Locations (3)

2004

Infectious Clinical Hospital (n.a. Toma Ciorba) Department 5, Chisinau

Infectious Clinical Hospital (n.a. Toma Ciorba), Department 4, Chisinau

2025

Repiblican Clinical Hospital (ARENSIA unit), Chisinau

All Listed Sponsors
lead

Replicor Inc.

INDUSTRY

NCT02565719 - REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection | Biotech Hunter | Biotech Hunter